Skip to main content

Tag: Medicine

Researchers Identify A New Genetic Risk Factor for Age-related Eye Disease

Age-related Macular Degeneration (AMD) is a leading cause for loss of eyesight at an advanced age.

Researchers at Tel Aviv University identified a new genetic risk factor for the complex eye disease AMD (Age-related Macular Degeneration), a leading cause for loss of eyesight at an advanced age. For the first time, the researchers identified proteins that play a key role in the development and functioning of the tissue affected by the disease, found their exact sites in the genome, and discovered the connection between variations in these genomic regions and the risk for AMD. The researchers: “The new discovery enhances our understanding of the previously unknown function of genomic regions outside the genes. The method we applied may enable the deciphering of additional genetic mechanisms involved in various complex genetic diseases.”

 

“Comparative studies have identified whole genomic regions that are probably related to the disease but were unable to pinpoint any specific feature in these regions and define it as a risk factor. Our study addressed this problem.” Prof. Ran Elkon

 

Decoding Mechanisms of a Complex Disease

The study was led by Prof. Ruth Ashery-Padan and Prof. Ran Elkon and their research teams, Mazal Cohen Gulkar, Naama Mesika, Ahuvit David, and May Eshel, from the Department of Human Molecular Genetics and Biochemistry at the Sackler Faculty of Medicine and the Sagol School of Neuroscience at Tel Aviv University. The paper was published in PLOS Biology.

Prof. Ashery-Padan explains that “one of the greater challenges in genetic research today is decoding the genetic mechanisms of complex diseases caused by a combination of several different genetic and environmental factors (rather than an identifiable defect in a single gene). Diabetes, bowel diseases, and various mental illnesses are just a few examples. In our study we chose to focus on AMD, which causes degeneration of the central retina – a major cause of loss of vision at an advanced age in developed countries.”

Prof. Elkon adds: “AMD has a significant genetic component. Studies comparing the genomes of people with and without AMD (as well as a range of other complex genetic diseases) have found differences in several genomic regions, probably associated with risk factors for the disease. However, these differences were not detected in any specific gene, but rather in the extensive regions that stretch between the genes, whose functions and modes of operation are still largely unknown. In fact, comparative studies have identified whole genomic regions that are probably related to the disease but were unable to pinpoint any specific feature in these regions and define it as a risk factor. Our study addressed this problem.”

The study focused on the cells of a layer of tissue called retinal pigmented epithelium (RPE), which supports photoreceptors in the retina, and is essential for their initial development as well as their survival throughout an individual’s lifetime. According to the researchers, this tissue is affected right from the earliest stages of AMD.

 

Prof. Ruth Ashery-Padan

 

“Our findings provide new insight into a previously unsolved issue: the functions and mode of operation of genomic sequences located outside the genes, and how they are involved in complex genetic diseases.” Prof. Ruth Ashery-Padan

 

Novel Research Methodology

“First, we wanted to understand the genetic mechanism that activates and regulates the specific activity of pigmented epithelium cells,” says Prof. Ashery-Padan. “Through a series of experiments, knocking down different proteins in both a mouse model and human cells, we identified two key proteins, LHX2 and OTX2, which together dictate the expression of many genes unique to this tissue. The proteins act as transcriptional activators – binding to specific regulatory sites in the genome to determine which genes will be expressed in a particular cell.”

The next challenge was mapping the precise locations of the two proteins in the genome. The researchers used the innovative technology ChIP-seq – a DNA sequencing method that identifies binding sites where proteins bind to the DNA.

“We found that the binding sites of the two proteins were quite close to each other,” explains Prof. Elkon. “Moreover, these same sites had previously been identified as related to risk factors for AMD (namely, sequences that showed differences between people with and without AMD). We assume that due to changes in DNA sequences in these genomic regions, transcriptional proteins cannot easily find and bind with their binding sites. This reduces the expression of the nearby gene regulated by the transcriptional proteins, which encodes an ion channel known as important to eye function. The decrease in the gene’s activity affects the entire tissue, increasing the risk for development of AMD.”

Prof. Ashery-Padan sums up the study: “In our study we identified two proteins related to risk factors for the complex genetic eye disease AMD. In addition, for the first time, we were able to map the exact genomic sites of these proteins and found that they operate in a region previously identified as related to risk factors for AMD. Our findings provide new insight into a previously unsolved issue: the functions and mode of operation of genomic sequences located outside the genes, and how they are involved in complex genetic diseases. We believe that our novel research methodology will enable the identification and mapping of many other genetic mechanisms related to AMD and other complex genetic diseases.”

People With Autism Experience Pain at a Higher Intensity

Findings contradict prevalent belief that people on the autism spectrum are ‘indifferent to pain’.

A new study examined the pain perception among people with autism and found that they experience pain at a higher intensity than the general population and are less adaptable to the sensation. This finding is contrary to the prevalent belief that people with autism are supposedly ‘indifferent to pain’. The researchers expressed the hope that the findings of their study will lead to more appropriate treatment on the part of medical staff, caregivers, and parents toward people with autism, who do not always express the experience of pain in the usual way.

The study was funded by the Israel Science Foundation and was led by four researchers: Dr. Tami Bar-Shalita of the Sackler Faculty of Medicine at Tel Aviv University who initiated the study, Dr. Yelena Granovsky of the Technion and Rambam Medical Center, and Prof. Irit Weissman-Fogel and Prof. Eynat Gal of the University of Haifa. This study constitutes a framework for the theses of PhD students Tzeela Hofmann and Mary Klingel-Levy, and three articles based on it have already been published or approved for publishing. The present study has been published in the prestigious PAIN journal.

 

“We know that self-harm could stem from attempts to suppress pain, and it could be that [people with autism] hurt themselves to activate, unconsciously, a physical mechanism of ‘pain inhibits pain’.” Dr. Tami Bar-Shalita

 

Self-harm Not Proof of Indifference to Pain

“Approximately 10% of the general population suffer from sensory modulation dysfunction, which means sensory hypersensitivity at a level that compromises normal daily functioning and quality of life. These people have difficulty, for example, ignoring or adapting to buzzing or flickering of fluorescent lights, humming of air conditioners or fans, or the crunching of popcorn by someone sitting next to them in the cinema,” explains Dr. Bar-Shalita.

“In previous studies in the lab we found that these people suffer from pain more than those without sensory modulation dysfunction. Since it is known that sensory modulation dysfunction occurs in   people with autism at a rate of 70-90%, it constitutes a criterion for diagnosing autism, and is associated with its severity. We were interested in exploring pain perception in autism, so we asked: do people with autism hurt more than the general population? This question was hardly studied in the lab before we got started.”

According to the researchers, for many years the prevalent opinion was that ‘people with autism hurt less’ or that they were ‘indifferent to pain’. Actually, ‘indifference to pain’ is one of the characteristics presented in the current diagnostic criteria of autism.

The proof of this was, supposedly, their tendency to inflict pain on themselves by self-harm. 

Dr. Bar-Shalita: “this assumption is not necessarily true. We know that self-harm could stem from attempts to suppress pain, and it could be that they hurt themselves to activate, unconsciously, a physical mechanism of ‘pain inhibits pain’.”

 

“The results of our study indicate that in most cases, the sensitivity to pain of people with autism is higher than that of most of the population, while at the same time they are unsuccessful at effectively suppressing painful stimuli.” Dr. Tami Bar-Shalita

 

Dr. Tami Bar-Shalita

Contributing to Advancement of Personalized Treatment

This study is a laboratory pain study approved by the ethics committee of the academic institutions and Rambam Medical Center. The study included 52 adults with high-functioning autism (HFA) and normal intelligence – hitherto the largest reported sample in the world in studies on pain among people with autism. The study made use of psychophysical tests to evaluate pain, commonly used in the area of pain study. These methods examine the link between stimulus and response, while the researcher, using a computer, controls the duration and intensity of stimulus and the examinee is asked to rank the intensity of the pain felt by him on a scale of 0 to 100.

The findings have proven beyond doubt that people with autism hurt more. Furthermore, their pain suppression mechanism is less effective.

The researchers conducted a variety of measurements, aimed among other things at examining whether the hypersensitivity to pain derives from a sensitized nervous system or from suppression of mechanisms that are supposed to enable adjustment and, over time, reduce the response to the stimulus. They found that in the case of people with autism, it is a combination of the two: an increase of the pain signal along with a less effective pain inhibition mechanism.

Dr. Bar-Shalita concludes: “our study constituted a comprehensive, in-depth study of the intensity of pain experienced by people with autism. The prevalent belief was that they are supposedly ‘indifferent to pain’, and there are reports that medical and other professional staff treated them accordingly. The results of our study indicate that in most cases, the sensitivity to pain of people with autism is higher than that of most of the population, while at the same time they are unsuccessful at effectively suppressing painful stimuli. We hope that our findings will benefit the professionals and practitioners handling this population and contribute to the advancement of personalized treatment.”

In additional articles soon to be published, the researchers have examined the brain activity of people with autism during pain stimuli, and sub-groups within this population concerning their perception of pain.

Researchers Uncover New Factors Linked to Williams Syndrome

Findings may contribute to development of treatments to enable normal expression of genes essential for brain development in people suffering from the syndrome.

Williams syndrome is a relatively rare, multisystem genetic syndrome that causes disorders in brain development. A new study by the Tel Aviv University and Hebrew University found that abnormal processes lead to disruption in the expression of genes essential for brain development in people suffering from the syndrome. The researchers believe their findings may contribute to the future development of targeted treatments that will enable normal expression of the affected genes identified in the research.

Looking Beyond Chromosome 7

The research was led by Dr. Boaz Barak from the School of Psychological Sciences and the Sagol School of Neuroscience at Tel Aviv University and Dr. Asaf Marco from the Faculty of Agriculture, Food and Environment of the Hebrew University. Also participating in the research were Dr. Sari Trangle, Mr. Gilad Levy and Ms. Ela Bar from Dr. Barak’s laboratory, and Dr. Tali Rosenberg and Ms. Hadar Parnas from Dr. Marco’s laboratory. The research findings were published in the prestigious journal Molecular Psychiatry from the Nature publishing group.

 

“We wanted to examine whether the Williams Syndrome is also characterized by defects in the genomes contained in brain cells which prevent the proper expression of essential genes.” Dr. Boaz Barak

 

Dr. Barak: “Williams syndrome is a rare, multisystem genetic syndrome that includes disorders in brain development that lead to heightened social interactions, mental retardation, and other characteristic features. Past research has revealed that twenty-five genes are missing from the DNA on chromosome number seven of people with Williams syndrome, and the study of the syndrome to date has mainly focused on those missing genes and their functions.”

“We wanted to examine whether the syndrome is also characterized by defects in the genomes contained in brain cells which prevent the proper expression of essential genes. Specifically, we asked: ‘Is it possible that certain genes are not expressed properly in the brains of people with Williams syndrome due to the phenomenon of methylation – when a molecule known as a ‘methyl group’ is located on a certain gene that is present in the genome, preventing it from expressing itself properly?”.

To illustrate the phenomenon of the missing genes, Dr. Barak took an instruction book in which some of the pages were torn out. As a result of the missing pages, anyone following the instructions would make mistakes. Similarly, hiding some of the letters in the pages left in the book with a black marker would result in instructions being corrupted, just like methylation on an existing gene disrupts its expression.

Methylation is in many cases a normal mechanism in the cells of the body, as its role is to prevent expression of certain genes when appropriate. However, when there are disruptions in the correct application of methylation, the abnormal expression of the genes may lead to impairments in cell function, and subsequently cause damage to various organs, including to normal brain development.

 

Dr. Boaz Barak  from the School of Psychological Sciences and the Sagol School of Neuroscience at Tel Aviv University

Uncovering New Factors

The researchers examined human brain tissues taken from adults with and without Williams syndrome who died of causes unrelated to the syndrome and donated their brains to science.

“We focused on samples from the frontal lobe, the area of the brain that is responsible for brain functions such as cognition and decision-making,” Dr. Barak explained. “In a previous study, we located in this area damage to the characteristics of the nerve cells and the cells that support nerve cell activity in people with Williams syndrome. In this study, we examined all the genes in all the cells of the frontal lobe to determine whether there are genes in people with Williams syndrome that have undergone abnormal methylation processes, i.e., increased or decreased gene silencing compared to a brain with typical development.”

 

“We uncovered significant information about the defective expression of genes in people with Williams syndrome. While these genes are fully present in the genome of the brain cells, until now it was not known that these abnormally regulated genes are involved in the syndrome.” Dr. Asaf Marco.

 

The researchers found that indeed in people with Williams syndrome abnormal methylation does exist in this area of the brain, resulting in disruption of the normal expression of many genes related to the normal development of the brain’s neural functions, such as regulation of social behavior (people with Williams syndrome are known to be overly friendly), cognition, plasticity of the brain, and cell survival.

“We uncovered significant information about the defective expression of genes in people with Williams syndrome. While these genes are fully present in the genome of the brain cells, until now it was not known that these abnormally regulated genes are involved in the syndrome,” says Dr. Marco.

 

“Building on our findings, it will be possible to focus future efforts on the development of targeted treatments that will reach the disrupted sites that we identified in the study in order to ‘correct’ the defective expressions.” Dr. Boaz Barak

 

Next Step: Target Disrupted Sites

“In addition, one of our main findings is that the disruptions in methylation do not have to appear near the gene whose function is impaired, and sometimes the disruptions are located far away from it. This information is critical because it allows us to better understand the spatial organization of DNA and its effect on gene control.”

He adds that, “since we know of enzymes that are able to remove or add methyl molecules, the next challenge will be to precisely direct those enzymes to the disrupted sites identified in our research, with the aim of allowing the genes to be properly expressed.”

Dr. Barak concludes: “Our research revealed new factors related to the disabilities that characterize Williams syndrome. Instead of focusing on the effects of the missing gene, as has been done until now, we shed light on many more genes that are expressed in a defective manner. Building on our findings, it will be possible to focus future efforts on the development of targeted treatments that will reach the disrupted sites that we identified in the study in order to ‘correct’ the defective expressions.”

Lessons in Tolerance and DNA Extraction in Tel Aviv University’s Medical Labs

High school students on the autism spectrum were integrated for a whole semester in the research laboratories of TAU’s Faculty of Medicine.

A hugely successful pilot project was concluded in Tel Aviv University’s Sackler Faculty of Medicine, in which nine curious high school students on the autism spectrum from the Ahad Ha’Am School in Petah Tikva (a city in the Central District of Israel) were integrated in the University’s medicine labs for one semester. In the labs, the highschoolers experienced research and teamwork under the guidance of TAU medical students and doctoral students. Together, they programmed codes for research analyses, grew bacteria, extracted DNA, and other fascinating activities.

All good things come to an end, and a touching farewell ceremony was held on campus last week. Good news is, because of the project’s success there are now plans to expand the program to include additional School of Medicine labs.

Opening the Labs

The special project was launched by Sharon Naor, a TAU PhD graduate student of the Faculty of Medicine, and Prof. Karen Avraham, Dean of the Faculty, in collaboration with Kobi Malka, Director the of the “גדולים במדים” (“Big in Uniform”) program of the Lend a Hand to a Special Child association. Malka’s program typically works to integrate children on the autistic spectrum into the army.

The project consisted of two-hour sessions every week for an entire semester. Every week, the youth met with graduate and doctoral students who generously contributed their time and knowledge in seven different medical laboratories that were allocated for the project. 

 

Mutual contribution (from left to right): Lily Trossman and Dr. Moran Goren, who took part in the project together

 

“One of the [TAU] students told me during the semester: ‘I’m learning to be more tolerant and to listen to someone who thinks at a different pace. It doesn’t mean that the person is less talented than me.’ In other words: ‘I came to teach and left educated'” Dr. Sharon Naor

 

Came to Teach and Left Educated

“We thought it would be a good idea to introduce young people diagnosed on the autistic spectrum to the world of science, explains Dr. Sharon Naor. “We’re not talking about a day of fun, but to bring them inside some of Tel Aviv University’s many labs and let them be a part of what’s going on there for some time. Who knows, maybe the experience will inspire some of them to become scientists themselves one day,” he muses.

He is convinced that the sessions were mutually beneficial for the highschoolers and for the University students: “One of the graduate students told me during the semester: ‘I’m learning to be more tolerant and to listen to someone who thinks at a different pace. It doesn’t mean that the person is less talented than me.’ In other words, the student joined the project with the intention to teach and was surprised to leave the experience educated.” 

The Dean of Medicine agrees that both highschoolers and students benefitted from the project. Addressing the participants from her Faculty, Prof. Karen Avraham commended the students for dedicating their time to this project and added: “I believe that these two hours a week have nurtured something inside you as well, and that the project opens our hearts. I have no doubt that we will continue this wonderful project.”

 

“What helps build a better society are small human actions, the ability to pay attention to the needs of other people, and to look for ways to accommodate and to provide a suitable response.” Yael Bezalel Zhelezni

 

While We’re on the Topic of the Heart… 

“We work hard to prepare our students for the future by familiarizing them with various systems and institutions that they will encounter, such as the military system, the employment system… and this year we got the opportunity to introduce them to the academic system as well!” said Yael Bezalel Zhelezni, Director of the Ahad Ha’Am School, addressing TAU’s academic staff. She and her staff had witnessed the participating highschoolers’ great excitement about the lab sessions during the semester.

“What helps build a better society are small human actions, the ability to pay attention to the needs of other people, and to look for ways to accommodate and provide a suitable response. This project is a lesson in modesty, respect and friendship… and perhaps the most important lesson they will receive in their lives: how to be a person who sees the other and their needs (…) We are all different in some way or another.”

She noted that, “whereas the apparent target may be our young students, the real target of education in this project is society at large” 

Bezalel Zhelezni expressed her hope for the future generation of health professionals: “I hope, dear students, that these encounters will stay with you in the future, when you provide the most important care for humanity – medical care. And as for the lecturers among you: beyond producing talented new doctors, I hope that you will also pass on a sensitivity to this special group within our population. And that you will do so with pride.”

Featured Image: The project’s trainees, supervising students and Prof. Karen Avraham, Dean of the Faculty of Medicine

Medical Clowns – No Laughing Matter

Israeli researchers find that medical clowns contribute significantly to the achievement of medical therapeutic goals.

You see them stroll around in the hospitals’ toughest wards with their red noses, colorful clothes, and unwavering smiles, spreading laughter and cheerfulness wherever they go. They are the medical clowns: trained professionals whose goal is to change the hospital environment through humor. 

A new study tested and categorized the skills of medical clowns and found that their importance goes far beyond contributing to a patient’s good mood. The researchers identified 40 different skills of medical clowns, including establishing an emotional connection and creating a personal relationship with the patient, expressing the patient’s frustrations and difficulties to the medical staff, increasing the patient’s motivation to adhere to medical treatment, distracting the patient from pain, and creating a joyful atmosphere.

 

Medical clowns working alongside other therapists (Photo: The Dream Doctors Project, Medical Clowning in Action)

Not Just for Entertainment Purposes

The research was conducted under the leadership of Prof. Orit Karnieli-Miller, with Dr. Lior Rosenthal, both from the Department of Medical Education at TAU’s Sackler Faculty of Medicine, in collaboration with Ms. Orna Divon-Ophir, Dr. Doron Sagi, Prof. Amitai Ziv and Ms. Liat Pessach-Gelblum from the Israel Center for Medical Simulation (MSR). The study was published in Qualitative Health Research, a leading journal in the field of health.

The researchers show that not only do medical clowns help the patients and their family members, but also the medical team and the achievement of treatment goals.

Through use of different communication skills, clowns make it easier for the patient to cooperate with various treatments. The medical clowns work in a team with other therapists, know how to intervene and help whenever an argument or crisis should arise to advance treatment.

 

“From the moment they enter the room, the clowns form a bond with the patients, strengthen them, and give them power and status within the medical system.” Prof. Orit Karnieli-Miller. 

 

Decoding their “Secret Magic”

Studies conducted throughout the years have shown the clowns’ positive influence on the hospital environment through humor, as well as helping patients deal with pain. However, no studies have empirically mapped the skills they use and their therapeutic goals to help understand their “secret magic.” In addition, there was a lack of broad understanding of how clowns can help children, teenagers, and their parents in various challenging situations of distress and difficulty, as well as how they can help patients and medical teams achieve treatment goals. This lack of appreciation of the potential benefits of utilizing the services of medical clowns meant that patients and medical teams would occasionally be reluctant to cooperate with them.

As part of the new study, the researchers focused on qualitative, in-depth systematic identification of the skills of medical clowns through observation and analysis of their actions in challenging encounters with adolescents, parents, and medical staff.

 

Medical clowns help patients and medical teams achieve treatment goals (Photo: The Dream Doctors Project, Medical Clowning in Action)

The team analyzed videotaped sessions of medical clowns in various simulated situations and conducted in-depth interviews with expert medical clowns. The researchers identified 40 different skills used by the medical clowns to achieve four therapeutic goals:

1) building a relationship and connecting to the needs and desires of the patients

2) dealing with emotions and difficulties

3) increasing the patient’s motivation to adhere to the treatment plan

4) increasing the patient’s sense of control and providing encouragement to patients

The clowns examined in the study were trained and recruited by the “Dream Doctors Project”, a non-profit association that employs medical clowns as part of the paramedical system in Israeli hospitals, and trains them to work within multi-disciplinary teams. The Tel Aviv University researchers collaborated with the Israel Center for Medical Simulation (MSR), which created a simulation-based workshop focused on developing the skills of experienced medical clowns.

“From the moment they enter the room, the clowns form a bond with the patients, strengthen them, and give them power and status within the medical system,” explains Prof. Karnieli-Miller. “They do this through an initial connection to the patients’ voice, and even to the patients’ reluctance to implement therapeutic recommendations – an emotional connection that often results in the patient changing their position and cooperating with the medical staff.”

 

Providing the patient with an increased sense of control and courage to face their challenges (Photo: The Dream Doctors Project, Medical Clowning in Action)

According to Prof. Karnieli-Miller the medical system is hierarchical, and it is not always easy for patients to navigate. Therefore, one of the skills of medical clowns is to place themselves in the lowest position in the medical setting. By doing so, they empower the patients by giving them a sense of power and control, including the choice of whether to allow the clown to enter the room as well as to dictate the nature of the patient’s role vis-à-vis that of the clown. This provides the patient with an increased sense of control and courage to face their challenges.

The researchers emphasize that the clowns are very aware of the emotional difficulty associated with staying in a hospital and dealing with an illness. To help deal with these issues, the clowns sometimes distract the patient by using props, humor, and imagination. Other skills include allowing the patient to direct their frustrations towards them, away from medical staff or parents.

Depending on the situation the clowns may also use a comforting touch, soothing music, empathetic listening, or a reinforcing statement to provide an environment where the patient feels comfortable to express their feelings. A patient’s ability to gain legitimacy is important and is strengthened by the clowns.

 

Prof. Orit Karnieli-Miller

 

“Mapping the skills and goals of the medical clowns improves their understanding of their role and may help other health professionals appreciate their work methods and the benefits of incorporating these methods into their own practices when faced with similar challenges” Prof. Orit Karnieli-Miller.

 

Learning from Medical Clowns’ Methods

“Mapping the skills and goals of the medical clowns improves their understanding of their role and may help other health professionals appreciate their work methods and the benefits of incorporating these methods into their own practices when faced with similar challenges,” adds Prof. Karnieli-Miller.

“This research is important because it allows the clowns to enhance their training program and refine their diverse skills to achieve the various therapeutic goals appropriate for different patients, as well as helping health professionals collaborate with the medical clowns. If professionals in the healthcare field gain a clear understanding of how and when to cooperate with the medical clowns, they will be able to help patients overcome challenges, and at the same time they may be more tolerant of the clowns’ ‘disruption’ of the hospital care regimen. This appreciation of the clowns’ contribution will provide the clowns with the time and space to connect with patients and help and encourage patients to become more active participants in their treatment plan,” she concludes.

Featured image: Medical clown with happy customer (Photo: The Dream Doctors Project, Medical Clowning in Action)

Tel Aviv University’s First MedTech Hackathon Sets a High Bar

200 students from six different disciplines find practical solutions to burning challenges in Israeli medicine.

TAU’s first competition for medical innovation ended last weekend (January 11-13) with spectacular results. The TAU MedTech Hackathon, organized by four entrepreneurial students from Tel Aviv University’s faculties of Medicine and Engineering, included 200 students who participated alongside 120 mentors and 30 judges from Israeli medicine and hi-tech. They shared the common goal of finding solutions for today’s burning medical problems. 

Burning Challenges from Israel’s Medical Industry

TAU students from Medicine, Engineering, Computer Science, Bioinformatics, Neuroscience, and Sofaer Global MBA (the flagship global MBA program of the Coller School of Management) worked together in 34 interdisciplinary teams for over 40 hours to come up with practical solutions to critical issues as defined by selected Israeli organizations and hospitals

Among the problems: finding a technological solution for early detection of peripartum depression (depression occurring during pregnancy and/or after childbirth); providing remote healthcare to ease the burden on hospitals and individuals who are physically challenged; inventing a new and safe device for brain water drainage in cases of hydrocephalus (a life threatening condition in children), and more.

The participants were not left to their own devices: each team was assigned two mentors, one from the medical world and another from the technological world, each leader in their field. In addition, the participants could join lectures and TED-style talks by industry experts.

Among the 200 participants were 30 international students, eight of them from Sofaer Global MBA. “The hackathon was an amazing experience which allowed our students to help their teams with the business side of the process and implement the knowledge they already gained through their studies into this real life experience. Impact entrepreneurship is the kind of entrepreneurship that we are encouraging and supporting at Sofaer,” said Jackie Goren, Head of the Program and one of the mentors at the hackathon. 

Student Initiative

The students who launched the ambitious initiative were Tom Zukerman, Yael Lieber and Orr Erlich – all third-year medical students, and Ilan Peerutin, a third-year dual B.sc Biomedical Engineering, Biology and Neuroscience student.

Together, the four recruited support from international tech and biomedical engineering giants, as well as hospitals and health care funds. Noteworthy sponsors included: The Massachusetts Institute of Technology, AWS, Meuhedet, Sackler Faculty of Medicine, TAU’s Entrepreneurship Center, Teva, Ichilov Tech, Novartis, Startup Nation Central, Philips and the Sagol Center for Regenerative Medicine.

Tel Aviv University encourages entrepreneurial activities for and by its students, and Prof. Karen Avraham, TAU’s Dean of Medicine, supported the students throughout the process: “This was an incredible initiative, and it came entirely from the students. They asked me if the Faculty of Medicine would support the project, and I immediately agreed (…) This hackathon is particularly thrilling because it is not a given that students would dedicate their time and make the effort required to mobilize so many stakeholders to come up with solutions to save people’s lives and health,” she said. 

And the Winners Are… 

Making the Operating Room Safer

The first prize went to team “OReye” from the Clalit Health Services’ general surgery challenge. Most aspects of patient safety in surgeries today are handled solely by the operating team. OReye utilizes cutting-edge computer vision technology to alleviate some of this responsibility, allowing the team to focus solely on the procedure. OReye’s mission is to improve patient safety in the operating room and reduce stress for surgical teams, making it a valuable tool in the operating room. Their project stood out for its originality, feasibility, and potential impact. 

The winning team will be flying to compete in the renowned Massachusetts Institute of Technology (MIT) medical hackathon competition “MIT Grand Hack,” scheduled for April 2023.

The team will also receive an AION Labs and Sanara Ventures accelerator package, which includes personal mentoring hours with experts, office space and professional tools to help develop their winning idea into a commercial startup.

 

The winning team and Prof. Karen Avraham (from left to right): Adi Sarig, Aviv Ziv, Prof. Karen Avraham, Idan Hezler, Eden Elbaz, Raz Naveh and Daphne Cavanaugh

Early Detection of Peripartum Depression

The runner-ups were the “Mommies,” who competed in the women’s health challenge from the Briah Foundation. The team created a community-based wellness app for the early diagnose and treatment of peripartum depression. “It is a true delight to create something for women,” says team member Juliana Gordon from the Sofaer MBA Program, and adds “This is just the beginning. Hopefully we will be able to impact millions of lives, benefitting society.” 

The team will receive ten mentoring sessions with experts from Weccelerate and the Israeli Leumit Health Services.

 

Team “Mommies” with Alon Pinhas from Weccelerate (from left to right): Juliana Gordon, Victoria Koval, Assaf Gadish, Mirit Halfon, Tal Beit Halevi, Shani Zach and Alon Pinhas (Weccelerate)

Personalized Treatment Plans for Breast Reduction 

Team “ABC3D” competed in the Tel Aviv Sourasky Medical Center Ichilov’s plastic surgery challenge. They developed a service that uses 3D models to create personalized treatment plans for breast reduction surgery. This enables advanced prediction and visualization ahead of surgery.

The team was awarded an entrance ticket to the JumpTAU accelerator program at TAU’s Entrepreneurship Center.

 

Team “ABC3D” with Yair Sakov, Head of TAU Entrepreneur Center (from left to right): Savion Cohen, Sarah Tannenbaum, Alaa Masarwa, Ido Shapira, Lydia Sokolovski and Yair Sakov (TAU Entrepreneur Center)

In addition, all the winning teams will receive legal advice, courtesy of leading Israeli commercial law firm Barnea Jaffa Lande.
 

“Prizes for such hackathons are usually monetary,” notes organizer Tom Zuckerman. “However, it was important to us that the winners receive tools and assistance to develop the skillsets needed to advance their initiatives.”

The Joy of the Process

How do the organizers summarize the event? The hackathon exceeded all their expectations: When we started this project, we didn’t imagine that so many people would believe in our vision. Those 40 hours were incredible; 200 talented and motivated students, accompanied by professionals and super-experienced mentors, and an extraordinary panel of judges. Seeing the results was fantastic, but following the process was an absolute joy.”

“We are already looking forward to next year’s hackathon, where we will continue to push the boundaries of medical innovation and positively impact the healthcare industry. In addition, we will be organizing other events during the year, and you’re all welcome to follow us to stay up to date!”

 

Tired but happy. TAU MEDTech organizers (from left to right) Tom Zuckerman, Orr Erlich, Yael Lieber and Ilan Peerutin

Researchers use Smartwatches to Measure Safety of COVID Vaccine

Tel Aviv University researchers monitored the physiological data of close to 5,000 Israelis over two years.

In a first-of-its-kind study, researchers at Tel Aviv University equipped close to 5,000 Israelis with smartwatches and monitored their physiological parameters over two years. Of those monitored, 2,038 received the booster dose of the coronavirus vaccine, allowing the researchers to objectively compare measures before and after the participants took the vaccine, and confirm its safety.

In addition, in collaboration with the Kahn Sagol Maccabi Research & Innovation Center (KSM – the research and innovation institute of the Israeli Maccabi Healthcare Services), the researchers examined the safety of the booster by analyzing the medical files of 250,000 members of Maccabi Health Services anonymously (without identifying details) and with the approval of the Helsinki Committee. From the analysis of this large amount of data, the researchers were able to evaluate the safety of the vaccines from three perspectives: subjectively – what the participant reports, objectively – what the watch detects, and clinically – what the doctor diagnoses.

 

“We saw clear and significant changes after administration of the vaccine (…) and then we saw a return to the participant’s baseline, i.e., the pulse levels after vaccination returned to their previous levels after six days. Hence, our study confirms the safety of the vaccine.” Prof. Dan Yamin

 

Confirming the Safety of the Vaccine

The research was carried out by PhD student Matan Yechezkel under the supervision of Prof. Dan Yamin, Head of the Laboratory for Epidemic Research and led in collaboration with Prof. Erez Shmueli, Head of the Big Data Laboratory, all from The Iby and Aladar Fleischman Faculty of Engineering at Tel Aviv University. Other collaborators were Dr. Tal Patalon and Dr. Sivan Gazit, Director and Deputy Director, respectively, of KSM, as well as Dr. Amichai Painsky and Ms. Merav Mofaz from Tel Aviv University. The results of the research were published in the prestigious journal, Lancet Respiratory Medicine.

As Prof. Yamin explains: “We wanted to test the safety of booster vaccines against the coronavirus. We conducted a large-scale, two-year clinical study during which we equipped 4,698 Israelis with smartwatches. The smartwatches were used to monitor several parameters such as heart rate, variation in heart activity, quality of sleep, number of daily steps taken, and more. In addition, the participants were asked to fill out daily questionnaires about their health status in a customized application that we developed. Finally, we analyzed data on potential unusual events from the medical files of a quarter of a million randomly selected, anonymous, insured members of the Maccabi Health Services.”

Since the medical file contains the date the booster vaccine was administered, researchers were able to compare the condition of the vaccinated patient with his/her baseline condition from 42 days before receiving the vaccine to the condition of 42 days after receiving the vaccine. The data was obtained from the questionnaires, smartwatches, and records of the Maccabi Health Fund.

 

Prof. Dan Yamin

“We saw clear and significant changes after administration of the vaccine, such as an increase in heart rate compared to the pulse rate measured before vaccination,” says Prof. Yamin, “and then we saw a return to the participant’s baseline, i.e., the pulse levels after vaccination returned to their previous levels after six days. Hence, our study confirms the safety of the vaccine.”

“The research also allowed us to compare subjective and objective indicators and medical diagnosis of the same participant who received the first booster and a few months later the second booster,” explains Prof. Yamin and adds, “We found no difference in the physiological response recorded by the smartwatches and that reported by the participant in the app.”

 

“The smartwatch sensors ‘felt’ that the vaccine was safe, the vaccinee himself reported that the vaccine was safe, and finally, the doctors determined that the vaccine was safe. The results of the study have far-reaching implications regarding objective testing of vaccine safety in the future.” Prof. Dan Yamin

 

Far-reaching Implications

In the medical literature, twenty-five unusual side effects attributed to the Corona vaccine were reported, and the researchers paid special attention to look for rare cases of inflammation of the heart muscle (myocarditis) and pericarditis. Prof. Yamin and his colleagues checked the frequency of these unusual side effects among a quarter of a million Maccabi members and found no increase in serious incidents of any kind associated with vaccination.

Prof. Yamin concludes: “If the watch reports any minor changes in the muscles, and the participant reports only significant changes he feels, the medical file tells us about unusual events diagnosed by the doctors as well as hospitalizations that may be related to vaccinations, with an emphasis on cardiac events. We did a comprehensive analysis of all those twenty-five unusual side effects, and we did not see an increase in their incidence among those receiving the booster. We found the vaccine to be safe to use. The smartwatch sensors ‘felt’ that the vaccine was safe, the vaccinee himself reported that the vaccine was safe, and finally, the doctors determined that the vaccine was safe. The results of the study have far-reaching implications regarding objective testing of vaccine safety in the future.”

Tel Aviv University Establishes Multidisciplinary Center for Research of Autoimmune Diseases

New center enabled by a generous gift of $10 million from Judith and Stewart Colton

Tel Aviv University has established the Colton Center, Israel’s first multidisciplinary center for the study of autoimmune diseases – chronic conditions involving an abnormal response of the immune system within body tissues. The Center will collaborate with Israel’s medical centers and health services including HMO’s and Hospitals as well as selected scientists from other academic institutions to enable big data analytics of medical information and biological samples from patients with autoimmune diseases and promote understanding of the causes of morbidity and recurrent flareups and possible early diagnostics and treatments.

The TAU research approach will be unique in its nature fundamentally being based on big data analytics that will direct any traditional scientific wet lab work. The intent of the center would be to grant research funding to multidisciplinary groups of scientists including computer science, engineering, biology, statistics, mathematics, psychology, and more. The different research programs will be managed based on agreed upon milestones with the ability to reach substantial sums upon success. In addition to its multidisciplinary clinical research, the new Center will encourage experimental and theoretical studies in immunology and conduct workshops and conferences jointly with the three other Colton Centers.

Goal: Finding a Cure for Autoimmune Diseases

The Center’s establishment was enabled by a generous donation of $10 million from TAU Governors Judith and Stewart Colton. It is the fourth research center founded by the Colton family to address autoimmune diseases, joining three centers already operating in the USA – at Yale University, the University of Pennsylvania, and NYU.

“Stewart and Judith Colton, renowned Jewish philanthropists and dear friends of TAU, have set themselves a goal,” explains Prof. Ariel Porat, President of TAU. This goal is “to develop drugs and treatments for autoimmune diseases. For this purpose, they have established dedicated centers at three leading American universities, and now decided to extend this activity to TAU.”

“This donation is following many years of active contribution by the Colton Foundation to TAU’s innovation and entrepreneurships in wide range of disciplines. We are proud to belong to this elite group of universities, and together with them and the Colton family, we will strive to find a cure for autoimmune diseases.”

 

“Even though autoimmune diseases have been known to science since the beginning of the 20th century, we still don’t have adequate tools for prevention, treatment, or prediction of morbidity and recurrent flareups.” Mr. Stewart Colton

 

Tel Aviv University 

In Need of Adequate Tools

Mr. Stewart Colton comments: “We believe the Consortium created by the four universities will multiply the opportunities for advancing the chances for successful research. We have worked with TAU for almost 40 years and recognize the unique talent and dedication brought to innovative science. It is a terrible disease that deserves more attention.”

“I am particularly proud that Prof. Uri Nevo from the Department of Biomedical Engineering, who was one of the Colton Fellow graduates, was appointed to be the Chair of the Center’s Steering Committee.”

“The category of autoimmune diseases covers over 100 diseases, with relatively familiar examples including lupus, multiple sclerosis (MS), psoriasis, and Crohn’s disease.  Autoimmune diseases are defined as diseases in which the immune system, instead of pathogens such as viruses and bacteria, or cells infected with these pathogens, attack the body’s healthy tissues. Even though autoimmune diseases have been known to science since the beginning of the 20th century, we still don’t have adequate tools for prevention, treatment, or prediction of morbidity and recurrent flareups.”

 

“The new Colton Center represents the best of basic and translational research – a true collaboration between researchers and clinicians to explore the optimal avenues for deciphering the mechanisms and therapy for autoimmune diseases.” Prof. Karen Avraham

 

True Collaboration Between Researchers and Clinicians

Prof. Karen Avraham, Dean of TAU’s Sackler Faculty of Medicine adds: “the new Colton Center represents the best of basic and translational research – a true collaboration between researchers and clinicians to explore the optimal avenues for deciphering the mechanisms and therapy for autoimmune diseases.”

 

“We will start our research carefully and modestly, hoping that from the focused study we will learn about the basic principles underlying autoimmune diseases, and eventually impact the understanding of many of these diseases, and benefit vast numbers of patients.” Prof. Uri Nevo

 

Aim to Benefit Vast Numbers of Patients

Prof. Uri Nevo from the Department of Biomedical Engineering, Chair of the Center’s Steering Committee, explains that the Center’s purpose is to promote the study and understanding of autoimmune diseases in order to improve their prevention and treatment. The first goal, he says, is to obtain measurable results, identify early signs and develop predictive algorithms for both initial onset and recurrent flare-ups. Eventually, studies may provide explanations, and possibly even discover the cause.

Other goals are to define practical recommendations for preventing onset and recurrence or reducing severity, and acquire new insights about disease mechanisms, enabling the development of new treatment strategies in the future.

Prof. Nevo: “Due to the complexity of the immune system, and the difficulty in measuring the interaction between the immune system and tissues in the body, we face some tough challenges. We do not understand the biological mechanism that drives many autoimmune diseases, or how they are connected with genetic and environmental risk factors. As a result, very few specific medications are on offer, and in many cases the disease becomes chronic.

“One of our main objectives is to establish research collaborations with various players: the medical institutions affiliated with TAU, the health services, and representatives of NPOs addressing the various diseases. Our intention is to sample their data and utilize the vast knowledge they have accumulated. The data will enable computerized analysis of samples taken from autoimmune patients in Israel, to help us understand the causes for the onset and recurrent flareups of these diseases.”

To choose the focus of its research for the next few years, the Colton Center is presently sending out a dedicated survey to thousands of clinicians and researchers in Israel. “We want to hear the opinions of doctors and experts, in order to focus on a limited number of diseases,” says Prof. Nevo. “We will start our research carefully and modestly, hoping that from the focused study we will learn about the basic principles underlying autoimmune diseases, and eventually impact the understanding of many of these diseases, and benefit vast numbers of patients.”

Featured image: Mr. and Mrs. Colton

Breakthrough in the Field of Controlled Drug Delivery

Tel Aviv University researchers develop new technology for efficient encapsulation and release of biomaterials.

In a world first, researchers found a way to control the encapsulation and release of molecules by exposure to UV light. The technology will advance the development of controlled release delivery systems for drugs and biomaterials.

Efficient encapsulation of molecules is considered a major technological challenge. The new technology, which allows for efficient encapsulation and high loading capacity of molecules, might address this need. The researchers estimate that the technology will lead to further development of delivery systems for controlled release of biomolecules and drugs in the body by external stimuli, using light.

Inspired by Measles

The research was led by PhD student Itai Katzir and supervised by Dr. Ayala Lampel from Shmunis School of Biomedicine and Cancer Research at The George S. Wise Faculty of Life Sciences at Tel Aviv University The study was published in the prestigious journal “Advanced Materials”.

The researchers explain that the new technology is inspired by viral compartments formed by the measles virus. Following infection of the host cell, the virus forms compartments that host all the reactions involved in the formation of new viral particles, a process which gives these compartments their name: viral factories. Recent studies show that these viral factories are in fact dynamic and liquid-like structures that are formed inside the host cell through a process called liquid-liquid phase separation.

Inspired by the viral protein, which is responsible for the formation of these factories, the researchers designed a “peptide” (= a short minimalistic protein) which forms compartments that resemble viral factories for encapsulation of biomolecules.

In addition, the researchers incorporated a unique element to the peptide sequence that enables a control of the encapsulation and release of molecules by irradiating the compartments using UV light.

 

“This technology opens opportunities for biomedical and biotechnological applications including encapsulation, delivery and release of drugs, protein, antibodies or other therapeutic molecules.” Dr. Ayala Lampel

 

Opens Opportunities for Biomedical and Biotechnological Applications

“Our goal was to engineer liquid-like compartments from a complex of peptide and RNA molecules that will enable efficient encapsulation of various biomolecules while keeping their native structure,” explains Dr. Lampel.

“The designed peptide and RNA form liquid-like compartments that resemble viral factories. We further developed these compartments to be stimuli-responsive by incorporating a protecting group to the peptide sequence that is cleaved following UV irradiation. The peptide with the photocleavable protecting group forms compartments with RNA, that have higher encapsulation efficiency for various molecules compared to compartments without the protecting group. We showed that by exposing the compartments to UV light and releasing the protecting group, we can control the release of encapsulated biomolecules.”

“Another unique property of this system is the high permeability and loading capacity of the encapsulated molecules, which is limited in part of the current technologies,” adds Dr. Lampel. “Thus, this technology opens opportunities for biomedical and biotechnological applications including encapsulation, delivery and release of drugs, protein, antibodies or other therapeutic molecules.”

Featured image: Dr. Ayala Lampel from TAU’s Shmunis School of Biomedicine and Cancer Research

Common Medications May Reduce Risk of Metastases after Colon and Rectal Cancer

Existing drugs to prevent anxiety, stress reactions and inflammation reduced the risk of the spread of cancer metastases after surgery to remove a colon tumor by tens of percent.

Although surgery to remove primary tumors is the mainstay of all cancer treatments, the risk of metastases after tumor removal is estimated at 35% among colon cancer patients, with higher risk in patients with more advance stages of the disease. However, a short, simple, and safe drug treatment developed at Tel Aviv University reduced the risk of the spread of cancer metastases after surgery to remove the primary tumor – according to the first clinical study of its kind conducted among 34 colon cancer patients operated on at Sheba Tel Hashomer Medical Center.

The research was led by Prof. Shamgar Ben-Eliyahu of TAU’s Sagol School of Neuroscience and School of Psychological Sciences at the Gershon H. Gordon Faculty of Social Sciences and Prof. Oded Zamora of TAU’s Sackler Faculty of Medicine, and its results were published in the European Journal of Surgical Oncology. At the same time, an overview of the theory and principles underlying the research was published in Nature Review Cancer.

“The stress during the waiting period for surgery, the stress and inflammation reactions that the body produces during the surgery itself and the physical recovery period, and finally the following anxiety of cancer recurring – all have an adverse effect on the body’s ability to fight metastatic processes,” explains Prof. Ben-Eliyahu. “These mental and physiological conditions create stress-inflammatory responses, which cause ample release of hormones from the prostaglandin and catecholamine families. These hormones suppress anti-metastatic immune activity, and thus encourage the development of metastases.”

“In addition, these hormones directly help the cancer cells that remain in the body even after surgery: due to exposure to these hormones, the cancerous tissue becomes more aggressive and metastatic. The good news is that we know how to treat both stress and inflammation using off-the-shelf medications.”

 

“This is a short, cheap drug treatment with no significant side effects. We deliberately sought the safest and cheapest drugs capable of lowering the body’s stress-inflammatory response to surgery, in order to save lives.” Prof. Shamgar Ben-Eliyahu

 

Significant and Encouraging Results

The researchers from Tel Aviv University gave 34 colon cancer patients two safe drugs that are available in every pharmacy: propranolol (Darlin), used to lower blood pressure and reduce anxiety, and etodolac (Etopan), used to prevent pain and inflammation.

Sixteen randomly chosen patients took the medication for 20 days – from five days before to two weeks after surgery at the Sheba Medical Center. The other 18 patients received placebo drugs (control group). Five years later, nine of the 18 patients who received the placebo (50%) developed cancer metastases, compared to two of the 16 patients who took Darlin and Etofen (12.5%).

“Although at five years after the operation, the statistical significance is clear, we need to conduct larger clinical studies,” says Prof. Ben-Eliyahu. “Our treatment reduced markers of metastasis in the tumor tissue and reduced the chances of cancer recurrence. This is a short, cheap drug treatment with no significant side effects. We deliberately sought the safest and cheapest drugs capable of lowering the body’s stress-inflammatory response to surgery, in order to save lives.”

“It sounds too good to be true, but similar results in breast cancer tissue were obtained in a study we conducted in 2017. Due to the small number of subjects in both studies, it is impossible to accurately estimate the magnitude of the beneficial effect, but the effects are statistically significant, meaning that they are not accidental.”

 

“We seek to save lives without financial gain, and we have received financial support from several Israeli and international sources, but these are insufficient for large clinical studies.” Prof. Shamgar  Ben-Eliyahu

 

Saving Lives Without Financial Gain

According to Prof. Ben-Eliyahu, part of the medical establishment distrusts the effects of stress-inflammatory reactions, particularly those resulting from psychological factors such as waiting for surgery or fear of the disease spreading. Another problem concerns the financing of clinical studies.

“One should bear in mind that the pharmaceutical companies have no financial incentive to support such studies. Our medicines are not patented; they are safe, cheap, and administered in a short treatment lasting just a few days. The drug companies look for patents on expensive drugs and prefer that the patient be dependent on the drug for the rest of their life.”

“Unfortunately, the major science foundations in Israel do not fund clinical research on drugs, assuming that the drug companies will fund them. We seek to save lives without financial gain, and we have received financial support from several Israeli and international sources, but these are insufficient for large clinical studies. I hope that funding will be found for a large-scale clinical study that we have now embarked on, with the intention of recruiting hundreds of colon and rectal cancer patients in Israel, because without such research – we will not be able to convince the medical establishment of the treatment’s effectiveness.”

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: [email protected]

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: [email protected]

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: [email protected]